{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Neuronal Signal Pathway > Acamprosate calciumCAS：77337-73-6
Molecular Formula：C10H20CaN2O8S2
Molecular Weight：400.48
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 77337-73-6 |
| Name | Acamprosate calcium |
| Molecular Formula | C10H20CaN2O8S2 |
| Molecular Weight | 400.48 |
| Solubility | Soluble in Water ≥4mg/mL(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00886588 |
| SMILES | CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2] |
| InChIKey | BUVGWDNTAWHSKI-UHFFFAOYSA-L |
| InChI | InChI=1S/2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8，9)10;/h2*2-4H2，1H3，(H，6，7)(H，8，9，10);/q;;+2/p-2 |
| PubChem CID | 155434 |
| Target Point | GABA Receptor |
| Passage | Neuronal Signaling;GPCR & G Protein |
| Background | Acamprosate calcium acts as a GABA receptor agonist and regulator of the glutaminergic system. |
| Biological Activity | Acamprosate calcium(Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction. IC50 value: Target: GABA receptor Acamprosate， or N-acetyl homotaurine， is an N-methyl-D-aspartate receptor modulator approved by the Food and Drug Administration (FDA) as a pharmacological treatment for alcohol dependence.Acamprosate has low bioavailability， but also has an excellent tolerability and safety profile. In comparison with naltrexone and disulfiram， which are the other FDA-approved treatments for alcohol dependence， acamprosate is unique in that it is not metabolized by the liver and is also not impacted by alcohol use， so can be administered to patients with hepatitis or liver disease (a common comorbid condition among individuals with alcohol dependence) and to patients who continue drinking alcohol. |
| Data Literature Source | [1]. Preuss UW. Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro e [2]. Witkiewitz K，Saville K，Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms，efficacy，and clinical utility. Ther Clin Risk Manag. 2012;8:45-53. [3]. Gahr M，et al. Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy.Nervenarzt. 2012 Aug 15. [4]. Palucha-Poniewiera A，Pilc A. Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):102-6. [5]. Hinton DJ，et al. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropharmacology. 2012 Jun;62(8):2480-8. |
| Unit | Bottle |
| Specification | 10mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
